Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203711 | 0.83 | LMNA (0.55) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| SCHEMBL29742219 | 0.83 | LMNA (0.55) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| Ammonia Solution, Strong SCHEMBL6035045 | 0.81 | LMNA (0.53) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| SCHEMBL2519637 | 0.79 | KDM4E (0.50) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| SCHEMBL3156746 | 0.78 | CCR1 (0.52) | KDM4EGPR3CYP1A2TSHRTOP2A | |
| SCHEMBL29661797 | 0.78 | CCR1 (0.52) | KDM4EGPR3CYP1A2TSHRTOP2A | |
| SCHEMBL26199339 | 0.76 | PARP1 (0.43) | KDM4EALDH1A1SMN1; SMN2MAOAACHE | |
| SCHEMBL5517493 | 0.75 | GPR3 (0.47) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| SCHEMBL201997 | 0.75 | MAOA (0.50) | NCF1KDM4EGPR3PI4KAPI4K2B | |
| SCHEMBL1191796 | 0.75 | NCF1 (0.50) | NCF1KDM4EGPR3PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515956-B | Benzimidazole derivative, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-115515956-A | Benzimidazole derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022068772-A1 | BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2021104441-A1 | POLYAROMATIC COMPOUND AS EGFR KINASE INHIBITOR | 江苏先声药业有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020216371-A1 | EGFR INHIBITOR AND APPLICATION THEREOF | 江苏先声药业有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9139538-B2 | Quinolinyl glucagon receptor modulators | PFIZER INC. (US) | 2015-09-22 | — | — | US | disclosed |
| WO-2013014569-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014569-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011027081-A2 | NOVEL DERIVATIVES OF 5,6,7,8-TETRAHYDROINDOLIZINE INHIBITING HSP90, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-10 | — | — | WO | disclosed |
| WO-2008041088-A2 | N-HYDROXY BENZAMIDES WITH ANTITUMOR ACTIVITY | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007054357-A1 | THIAZOLE ANALOGUES AND USES THEREOF | 4SC AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| EP-1785420-A1 | Thiazole analogues and uses thereof | 4SC AG (DE) | 2007-05-16 | — | — | EP | disclosed |
| US-20070060755-A1 | Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates | TEVA GYOGYSZERGYAR ZARTKORUEN MUKODO RESZVENYTARSASAG | 2007-03-15 | — | — | US | disclosed |
| US-20070020642-A1 | Structural interaction fingerprint | BIOGEN IDEC MA INC. | 2007-01-25 | — | — | US | disclosed |
| US-7166721-B2 | Preparation of 1H-imidazo[4,5-C] quinolin 4-amines via novel 1H-imidazo[4,5-c] quinolin 4-cyano and 1H-imidazo[4,5-c] quinolin 4-carboxamide intermediates | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) | 2007-01-23 | — | — | US | disclosed |
| US-4778811-A | CENTRAL NERVOUS SYSTEM DEPRESSANT | EGIS GYOGYSZERGYAR (HU) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060755-A1 | Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates | TLR7, IL4, P2RY4 | NCF1 1714/4885KDM4E 220/4885GPR3 1113/4885 |
| US-20150353508-A1 | QUINOLINYL GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | NCF1 3685/4885KDM4E 4299/4885GPR3 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.